Viking Therapeutics prices USD 225 million convertible senior notes offering

Viking Therapeutics priced an upsized USD 225 million offering of 2.00% convertible senior notes due 2032. Settlement is scheduled for Sept. 25, subject to customary closing conditions. Underwriters hold a 30-day option to buy up to an additional USD 33.75 million principal amount to cover over-allotments. Notes convert at an initial 19.7044 shares per USD 1,000, implying an initial conversion price of about USD 50.75. Net proceeds are estimated at about USD 218 million, earmarked mainly for VK2735 and VK3019 development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202609240705PR_NEWS_USPR_____LA55992) on September 24, 2026, and is solely responsible for the information contained therein. (C)